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I. The Significance of Apomixis? 
1) What is Apomixis? µ$SRPL[LV¶LVasexual reproduction through seeds IRXQGLQPDQ\µZLOG¶SODQWVSHFLHVHJGDQGHOLRQJUDVVHV
¾ It is uncommon among crop plants (except tropical forages, Citrus etc)
z Apomicts produce seed which contains a copy of the maternal genome
¾ 5HVHDUFKHUVDLPWRKDUQHVVWKLVDELOLW\µFORQLQJ¶"IRUDJULFXOWXUH
2) Why? µ$SRPL[LV7HFKQRORJ\¶ZRXOGWKHRUHWLFDOO\HQDEOHEUHHGHUVWRfix 
hybrid vigor & stablisise hybrid genomes
¾ This may benefit seed companies (e.g. reduced costs, diversify 
resources); and commercial and resource-poor farmers (e.g. recycle 
hybrid seed, fix cultivars for niche microclimates and specific uses)
3) What is the Timeline? Variable, contingent on scientific viewpoint and VXVWDLQHGLQYHVWPHQWµIURQWLHUUHVHDUFK¶
¾ In late 1990s, optimistic short-term goal of fully apomictic crop was 
predicated on dominance of interspecific hybridisation programmes
¾ Currently viewed as mid-to-long term goal, predicated on molecular bio, 
with gradual emergence of technological capability within 20 years
,7KH$SRPL[LV5HVHDUFK)LHOG«
1) The Apomixis research field is fragmented 
¾ $ORRVHO\LQWHJUDWHGVXUSULVLQJO\µVPDOO¶QHWZRUNFUHVHDUFKHUV
¾ With a range of foci and model systems
¾ With different approaches to technology devt., i.e. molecular biology in 
various forms, but increasingly few integrating plant breeding
2) Research has a diverse funding base
¾ Research is funded by the public sector, private sector, & PPPs
3) 7KHµ0ROHFXODU7XUQ¶
¾ The major transformation that has occurred over the last 10 years is the µmolecular turn¶
¾ i.e. the emergence of a molecular biology hegemony (shift from breeding 
to lab), with implications for technology models, stakeholders & end users
¾ Coinciding with private sector investment (late 1990s), related debates 
concerning IPR and apomixis e.g. Bellagio Declaration on necessity of 
enabling access to technology by resource-poor
¾ 7KHKLVWRULFDOFRQWH[WIRUWKHHPHUJHQFHDQGPDQDJHPHQWRIWKLV333«
II. Apomixis Consortium (1999-)
1) During 1990s, a leading team in Apomixis research was at CIMMYT
¾ French scientists based at CIMMYT, but some employed by IRD µ5HVHDUFK,QVWLWXWHIRU'HYHORSPHQW¶Tripsacum Program (1989-94); 
CIMMYT Apomixis Project (1994-99)
2) The team was trying to wide-FURVVPDL]HZLWKDZLOGDSRPLFWLFµUHODWLYH¶
Tripsacum (gamagrass)
¾ The team used the dominant technology in Apomixis research during this 
time: introgression, aided by lab-based molecular technology
¾ Goal was a non-*0µ$SRPL[LV7HFKQRORJ\¶LHfacultative apomictic 
maize ZKLFKZRXOGRFFDVLRQDOO\µVZLWFK¶WRVH[XDOUHSURGXFWLRQ
preserving genetic diversity (modelled on wild populations)
¾ Intended for resource-poor; resistant to IP; but may be uncontrollable
3) During mid-1990s they thought they were close to success
¾ Patent application filed, 1997
¾ Approched by Monsanto wanting exclusivity, reached agreement with 




The Apomixis Consortium (2009)
(post-2004)
II. Apomixis Consortium: Co-Innovation
1) What is the contributory structure of the Consortium?
¾ Decided on an annual basis, linked to 4-year agreement and plan?
2) Who provides what: Private Sector
¾ Cash support is provided by the Private Sector companies
¾ Each company contributes technologies & services (e.g. genetic materials for 
maize transformation, databases, further details undisclosed)
3) Who provides what: Public Sector
¾ IRD (and ANU post-2004) contribute by allocating two research scientist positions 
apiece to the project 
¾ CIMMYT has previously contributed research scientist position (in Mexico then 
ANU), support staff and costs for in-kind activities in Mexico 
z Its in-kind contribution was phased out in 2008 due to strategic re-emphasis of XQUHVWULFWHGIXQGVDQGUHODWHGGLVFUHSDQF\EHWZHHQ&,00<7¶VIRFXVRQDSSOLHGSODQWEUHHGLQJDQGFURSLPSURYHPHQWDQG333¶VVWUDWHJLFUHVHDUFKDJHQGD
¾ CIMMYT was committed to returning to in-kind contribution should research 
refocus on pre-breeding but as this is unlikely in phase 3, has withdrawn
4) Analysis: &RQWULEXWLRQVEDVHGRQDµFR-LQQRYDWLRQ¶VWUXFWXUH



























2000 2001 2002 2003 2004
Values = $; Source = CIMMYT Website
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II. Apomixis Consortium: Management 
1) What is the management structure of the Consortium? 
¾ 3URMHFWDFWLYLWLHVDUHPDQDJHGE\DQ³2YHUVLJKW&RPPLWWHH´
¾ This includes all PIs from the each of the public institutions 
¾ And one manager (scientist?) from each of the private sector partners
2) How does this work in practice?
¾ Each member is responsible for day-to-day coordination of their portion of 
the agreed activities that are conducted at their facilities
¾ Work-plans are collectively reviewed, revised and approved on a semi-
annual basis 
¾ Based on collective assessment of outputs from previous six months
3) Analysis: Effectiveness also related to authority of members within their 
institutions and the support of institutions for members; i.e. is Private 
Sector policy of placing scientists in managerial positions matched by 
Public Sector
z OC and its temporal structure is key to management of dynamic, 
emergent co-innovation process informed by frontier research
Oversight Committee
Composition: Chair, Public Sector PIs,
µ0DQDJHU¶IURPHDFK3ULYDWH6HFWRU3DUWQHU




II. Apomixis Consortium: IPR




¾ Farmers earning under $5,000 p.a. would receive Apomixis Technology 
IUHHZKLFKZDVIHDVLEOHJLYHQWKHJRDOZDVµQDWXUDO¶DSRPLFWLFPDL]H
2) Subsequent developments? All partners have contributed significant 
amounts of in-house legal time to IP management issues
¾ Under current agreement, market segmentation model is maintained
¾ Private Sect has non-exclusive licence to deploy outputs in target markets
¾ CIMMYT & IRD deliver to resource-poor farmers based on means test
3) Analysis: Stakeholders present for all potential end-users (importance of 
CIMMYT membership), but dependent on type of technology produced
¾ & are there consequences for freedom-to-operate if product integrates 
previously patented technology? (wider implications for co-innovation)
III. Discussion: Dynamics of Core Processes
Key Factors:
z Co-Innovation: 7KH$SRPL[LV&RQVRUWLXPLVD333IRXQGHGRQµ&R-,QQRYDWLRQ¶ZKHUHHDFKSDUWQHUDFWLYHO\SDUWLFLSDWHVLQWKHSURFHVVRI
planning, executing, and reviewing research
¾ And each partner contributes skills and resources that enable that process
2) µ)URQWLHU5HVHDUFK¶ The dynamics of co-innovation are structured by the IRFXVRIWKH333RQµIURQWLHU¶UHVHDUFK
¾ i.e. joint research with uncertain but very beneficial outcomes ± potentially 
a distinct trajectory from co-innovation but practically integrated
z What degree of uncertainty? Russian plant breeders and scientists first 
grasped the potential of apomixis for agriculture in the 1930s
¾ No significant progress until 1980s; still real uncertainty about when and 
how an apomictic technology can be delivered; but total confidence in its 
potential value
3) Dynamics: The interaction of managerial, organizational, contributory, and 



















Members: Public Sector 








End Users: Resource poor?
Timeline: Short-term, then uncertain     IPR: Open Source?
Eco-Risk: Uncontrollable?  Investment Risk: Low, then high?
DE NOVO CASSETTE 
Technology: GM Apomictic Crop
End Users: Diverse, contingent on tool design & cost
Timeline: 20 years? Contingent on level of investment  
IPR: Two-tier licence     Eco-Risk: Could be controlled?






































IV. Analysis: Benefits & Value
1) Dynamic temporal structure enables on-going review and management of evolving 
and emergent research trajectories
2) Co-innovation enables pooling of resources from leading stakeholders in different 
fields, and development and maintenance of rich project heritage
3) ,QIURQWLHUUHVHDUFK333HQDEOHVSDUWQHUVWRZRUNWRJHWKHULQµSUH-FRPSHWLWLYH¶
mode, reducing individual exposure to risk
¾ :LWKSURYLVLRQIRUµFRPSHWLWLYH¶PRGHZKHQEUHDNWKURXJKVRFFXUWKURXJK,35HWF
4) Strategic research reduces exposure via progress on valued topics e.g. endosperm 
devt. ± and contributions to the public good via research publications
4) Social Value: Diverse stakeholders cater for range of potential end-users
5) Apomixis technology might develop piecemeal: is PPP well-positioned?
¾ Different components of apomixis might gradually be incorporated into pre-breeding 
and product output (view of leading experts in field)
¾ In this regard, strategic research workstream is of future value
¾ Conclusion: Structure of co-innovation model for frontier research is robust?
IV. Analysis: Is the Model Robust?
1) Policy consensus: effective PPPs are central to future advances in agricultural 
biotechnology 
¾ Richards (2004) & others qualify this statement, acknowledging centrality of PPP PRGHOZKLOHFODLPLQJµDJUR-WHFKQRORJLFDOPRQRFXOWXUHV¶FDQVRPHWLPHVUHVWULFW
innovation; impede democratic impact of new biotech 
¾ Advocating attention to possibilities for diversification and competition between 
different approaches, both research paradigms and research infrastructures
2) How does this play out for Apomixis research? 
¾ µ0ROHFXODU7XUQ¶FUHDWHGDODE-based monoculture?
¾ %XW«DUHWHFKQRORJLFDOµKHWHURFXOWXUHV¶QHHGHGWRUHDOLVHDQµ$SRPL[LV7HFKQRORJ\¶"6RPHVFLHQWLVWVEHOLHYHWKDWde novo model will not deliver 
¾ & agro-technological diversification (inc. introgression) is the way forward
3) The Consortium: Key Shifts
¾ +HWHURFXOWXUHRIILHOG	ODEUHVHDUFKEHFDPHDPRQRFXOWXUHRIODEUHVHDUFK«
¾ Strategic research is now focused on GM solution? What form might technology 
take for resource-poor?
¾ Scientific challenges of frontier research and strategic research decisions 
have weakened co-GHSHQGHQF\LQ333«&,00<7ZLWKGUDZV
IV. Analysis: the Wider View?
1) Heterocultures, or Monocultures?
¾ In Apomixis PPPs / frontier research, there is a strong case for sustaining 
research flexibility to enable exploration and anticipate the emergent and 
XQNQRZQ«WKLVPD\EHPDQLIHVWHGDVDWUDQVLHQWµPRQRFXOWXUH¶"
¾ %XWUHFRJQLWLRQRIWKHYDOXHRIDUHVHDUFKµKHWHURFXOWXUH¶IRUVXVWDLQLQJD
partnership with a capacity to deliver for diverse end-users is also of 
significance
2) Need for Sustained Long-term Investment
¾ Sustained, intensified long-term investment needed to enable innovation 
in Apomixis / frontier research
¾ This will build capacity, increase the scope of the research field
¾ But conflicts with short-WHUPIXQGLQJDJHQGDV«
